Statement from TB Alliance on WHO Global TB Report 2016
“The newly released global tuberculosis (TB) report from World Health Organization (WHO) is reporting the grim reality that more people are […]
News
Kenya Becomes First Country to Introduce New Child-Friendly TB Medicines
27 September 2016 (Nairobi, Kenya) – TB Alliance is proud to announce the launch of new medicines for childhood tuberculosis
TB Alliance Statement on the UN’s Declaration on Antimicrobial Resistance
“TB Alliance welcomes the UN’s Political Declaration on Antimicrobial Resistance (AMR), which is an important step in mobilizing the political and
SciDev: Children Getting their Own Anti-TB Drugs Soon
This piece first appeared at SciDev.Net. Access the original story here. MANILA (August 25, 2016) Several countries are in a race to make
TB Alliance and Takeda Announce Advancement of Joint Program Investigating Promising Compounds for Novel TB Therapies
NEW YORK AND OSAKA (June 21, 2016) — TB Alliance and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced
TB Alliance and the Medicines Patent Pool Sign Memorandum of Understanding to Improve Access to TB Medicines in Resource-Limited Nations
NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum
New TB Clinical Trial Data-Sharing Platform Available for Researchers
TUCSON, Ariz., April 18, 2016 — The Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, and St.
Louder Than TB: TB Alliance joins health leaders to call attention to burden of childhood TB
On the occasion of World Tuberculosis (TB) Day, global health leaders from the “Louder Than TB Coalition” have come together
Phase 1 Clinical Trial of TB Drug Candidate TBA-354 Discontinued
NEW YORK, NY (March 11, 2016)—TB Alliance has announced that it has stopped the clinical development program for the tuberculosis
Phase 1 TBA-354 Placed on Clinical Hold
TB Alliance announced today that it has voluntarily halted further dosing of TBA-354 in the ongoing Multiple Ascending Dose (MAD)